SAN ANTONIO--(BUSINESS WIRE)--OncoVista, Inc., (OTC BB: AVUG) a biopharmaceutical company dedicated to developing innovative, safe and efficacious treatments for cancer, today announced that it has signed an exclusive, worldwide agreement to license a Phase II clinical candidate, OSI-7904L, from OSI Pharmaceuticals, Inc. of Melville, NY. Details of the license agreement were not disclosed.
